Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer
This study has been completed.
Baylor College of Medicine
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Teresa Hayes, Baylor College of Medicine
First received: February 14, 2008
Last updated: November 5, 2012
Last verified: November 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||July 2011|
|Primary Completion Date:||July 2011 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Sonpavde G, Wang M, Peterson LE, Wang HY, Joe T, Mims MP, Kadmon D, Ittmann MM, Wheeler TM, Gee AP, Wang RF, Hayes TG. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs. 2014 Apr;32(2):235-42. doi: 10.1007/s10637-013-9960-9. Epub 2013 Apr 23.